|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease显示文摘 | Achuthan Sourianarayanane Gaurav Garg Thomas H. Smith Mujtaba I. Butt Arthur J. McCullough Bo Shen | 2013 | Journal of Crohn’s and Colitis2013，，8： | 2 |
| 2 | Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease显示文摘 | Achuthan Sourianarayanane Gaurav Garg Thomas H. Smith Mujtaba I. Butt Arthur J. McCullough Bo Shen | 2013 | Journal of Crohn’s and Colitis2013，，8： | 1 |
| 3 | Resolving the age-related decline in central nervous system myelin turnover and drug discovery for oligodendroglial rejuvenation显示文摘Myel i n genes are amongst the most dysregulated genes in the aged brain:Just over half of the weight of an entire adult human brain is attributed to myelin,which wraps around neuronal axons and is essential for superfast axonal conduction and neuronal integrity.In the central nervous system,it is the function of specialized cells called oligodendrocytes(OLs)to make myelin,which is made up of lipids and proteins.OLs are generated throughout life by a significant population of oligodendrocyte progenitor cells(OPCs)that are responsible for the lifelong generation of OLs and myelin,essential for learning,as well as repair following pathological insults(i.e.in demyelinating diseases that include multiple sclerosis)(Simons and Nave,2015;Philips and Rothstein,2017).Changes in myelin content in the human brain over the lifespan of individuals have been well documented,as well as evidence of myelin loss in rodent models using classical histological approaches(Bartzokis et al.,2012;Soreq et al.,2017). | Andrea Domenico Rivera Arthur Morgan Butt Kasum Azim | 2022 | Neural Regeneration Research2022，17，12： | 1 |
| 4 | Astrocytes in human central nervous system diseases: a frontier for new therapies显示文摘Astroglia are a broad class of neural parenchymal cells primarily dedicated to homoeostasis and defence of the central nervous system(CNS).Astroglia contribute to the pathophysiology of all neurological and neuropsychiatric disorders in ways that can be either beneficial or detrimental to disorder outcome.Pathophysiological changes in astroglia can be primary or secondary and can result in gain or loss of functions.Astroglia respond to external,non-cell autonomous signals associated with any form of CNS pathology by undergoing complex and variable changes in their structure,molecular expression,and function.In addition,internally driven,cell autonomous changes of astroglial innate properties can lead to CNS pathologies.Astroglial pathophysiology is complex,with different pathophysiological cell states and cell phenotypes that are context-specific and vary with disorder,disorder-stage,comorbidities,age,and sex.Here,we classify astroglial pathophysiology into(i)reactive astrogliosis,(ii)astroglial atrophy with loss of function,(iii)astroglial degeneration and death,and(iv)astrocytopathies characterised by aberrant forms that drive disease.We review astroglial pathophysiology across the spectrum of human CNS diseases and disorders,including neurotrauma,stroke,neuroinfection,autoimmune attack and epilepsy,as well as neurodevelopmental,neurodegenerative,metabolic and neuropsychiatric disorders.Characterising cellular and molecular mechanisms of astroglial pathophysiology represents a new frontier to identify novel therapeutic strategies. | Alexei Verkhratsky Arthur Butt Baoman Li Peter Illes Robert Zorec Alexey Semyanov Yong Tang Michael V.Sofroniew | 2023 | Signal Transduction and Targeted Therapy2023，8，11： | 0 |
| 5 | Next generation drug connectivity mapping for acquiring therapeutic agents to differentially regulate myelination显示文摘The need for new therapeutic approaches:Conventional drug discovery is a lengthy and expensive process,taking decades and billions of dollars to get a drug from bench to bedside.Much of the costs incurred are at the pre-clinical stages,between drug design and synthesis to delineating the cellular“Mechanisms of Action”(MoA).Notably,there is a very high risk of failure,and only a very small proportion of therapeutic agents reach later-phase clinical trials.Accordingly,drug repositioning has become a valuable strategy aimed at fast-tracking treatments into clinical use and improving the chances of therapeutic success.A novel addition to this approach is connectivity mapping,which defines cell-specific transcriptional responses to small molecules in disease-dependent contexts.This commentary outlines how some of the latest innovations in connectivity mapping can be exploited for drug repurposing. | Kasum Azim Andrea Domenico Rivera Arthur Morgan Butt | 2023 | Neural Regeneration Research2023，18，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员